-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 10, 2021, the clinical trial application of Bailey Pharmaceuticals BL-B01D1 was accepted by NMPA
.
According to the information of Baili Pharmaceutical and its subsidiary SystImmune, BL-B01D1 is a new dual-anti-ADC drug
.
At the 4th China Biomedical Innovation Cooperation Conference to be opened on June 25, 2021, Dr.
Zhu Yi, chairman of Bailey Pharmaceuticals, was invited to give a special report on "Best-in-class ADC"
.
Since the application for the first ADC drug patent in 2015, there have been 25 patent families and a total of 65 formal patent applications in 13 countries and regions
After DS-8201 and Trodelvy, ADC ushered in a new round of upsurge, and domestic ADC new drug research and development also revived
.
In terms of targets, from HER singularization targets to Trop2 and Claudin 18.
2, the rapid emergence of Trop 2 ADCs has been reported.
At present, 6 Trop 2 ADCs have been declared.
In addition to the termination of Biotech, there are 5 more and Claudin 18.
2 ADCs have already declared 5
.
Bailey Pharmaceuticals BL-B01D1 is the only dual-target ADC.
Summary
Summary New targets and dual-antibody ADCs are becoming a focus of competition in the domestic ADC new drug field
.
Baili Pharmaceuticals is relatively advanced in the exploration of differentiation.
